Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.44 |
| ▸ | GGT1 | P19440 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31617745 | 1.00 | HTT (0.56) | HTTTP53FOLH1CYP2C9HIF1A | |
| SCHEMBL29104385 | 0.93 | ALDH1A1 (0.53) | HTTTP53FOLH1CYP2C9HIF1A | |
| SCHEMBL16245167 | 0.86 | TSHR (0.46) | HTTTP53CYP2C9HIF1AALDH1A1 | |
| SCHEMBL19320834 | 0.85 | MAPK1 (0.56) | HTTTP53FOLH1CYP2C9HIF1A | |
| SCHEMBL28857874 | 0.85 | HTT (0.50) | HTTTP53FOLH1CYP2C9HIF1A | |
| SCHEMBL4234379 | 0.85 | POLB (0.47) | HTTTP53FOLH1CYP2C9HIF1A | |
| SCHEMBL3145722 | 0.84 | LMNA (0.46) | HTTTP53ALDH1A1TSHRKDM4E | |
| SCHEMBL23453516 | 0.83 | TP53 (0.59) | HTTTP53FOLH1CYP2C9HIF1A | |
| SCHEMBL668837 | 0.83 | MRGPRX4 (0.56) | HTTTP53FOLH1CYP2C9HIF1A | |
| SCHEMBL1558507 | 0.83 | L3MBTL1 (0.51) | HTTCYP2C9ALDH1A1ALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109096107-B | Preparation method of 5-formyl-2-methoxy methyl benzoate | 山东轩德医药科技有限公司 | 2021-05-07 | — | — | CN | claimed |
| EP-3375883-B1 | METHOD FOR PRODUCING N EPSILON -ACYL-L-LYSINE | AJINOMOTO KK (JP) | 2021-02-03 | — | — | EP | claimed |
| US-10266857-B2 | Method for producing Nε-acyl-L-lysine | AJINOMOTO CO., INC. (JP) | 2019-04-23 | — | — | US | claimed |
| EP-3375883-A1 | METHOD FOR PRODUCING N EPSILON -ACYL-L-LYSINE | Ajinomoto Co., Inc. (JP) | 2018-09-19 | — | — | EP | claimed |
| US-20090321646-A1 | NON-DESTRUCTIVE ANALYSIS BY VIS-NIR SPECTROSCOPY OF FLUID(S) IN ITS ORIGINAL CONTAINER | THE AUSTRALIAN WINE RESEARCH INSTITUTE (AU) | 2009-12-31 | — | — | US | claimed |
| EP-1904828-A4 | NON-DESTRUCTIVE ANALYSIS BY VIS-NIR SPECTROSCOPY OF FLUID (S) IN ITS ORIGINAL CONTAINER | AUSTRALIAN WINE RES INST (AU) | 2008-11-19 | — | — | EP | claimed |
| EP-1904828-A1 | NON-DESTRUCTIVE ANALYSIS BY VIS-NIR SPECTROSCOPY OF FLUID (S) IN ITS ORIGINAL CONTAINER | The Australian Wine Research Institute (AU) | 2008-04-02 | — | — | EP | claimed |
| WO-2007006099-A1 | NON-DESTRUCTIVE ANALYSIS BY VIS-NIR SPECTROSCOPY OF FLUID (S) IN ITS ORIGINAL CONTAINER | THE AUSTRALIAN WINE RESEARCH INSTITUTE (AU) | 2007-01-18 | — | — | WO | claimed |
| WO-2002033404-A2 | INTEGRATED WINE QUALITY SENSOR | TRAUNER KENNETH B (US) | 2002-04-25 | — | — | WO | claimed |
| JP-2215809-A | — | — | None | — | — | JP | disclosed |
| US-20260007672-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2026-01-08 | — | — | US | disclosed |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2025-12-25 | — | — | US | disclosed |
| US-12491185-B2 | Inhibitors of mPTP | NRG THERAPEUTICS LTD (GB) | 2025-12-09 | — | — | US | disclosed |
| EP-4652162-A1 | INHIBITORS OF MPTP | NRG Therapeutics LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| JP-H02215809-A | PREPARATION OF CATALYST COMPONENT FOR OLEFIN POLYMERIZATION AND PRODUCTION OF OLEFIN | SHOWA DENKO KK | 1990-08-28 | — | — | JP | disclosed |
| US-4628126-A | Process for the production of dihydroxybenzenes | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1986-12-09 | — | — | US | disclosed |
| EP-0097289-B1 | AZO DYESTUFFS | BAYER AG (DE) | 1986-10-15 | — | — | EP | disclosed |
| US-4564514-A | Process for the production of water-free organic hydrogen peroxide solution | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1986-01-14 | — | — | US | disclosed |
| US-4563436-A | Catalyst component for α-olefin polymerization and method of producing the same | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1986-01-07 | — | — | US | disclosed |
| US-4551562-A | Process for the production of dihydroxybenzenes | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1985-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12491185-B2 | Inhibitors of mPTP | PARK7, PINK1, SNCA | HTT 233/4885TP53 4559/4885FOLH1 1499/4885 |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | HTT 4832/4885TP53 4753/4885FOLH1 3363/4885 |
| US-20260007672-A1 | INHIBITORS OF MPTP | PARK7, SNCA, CYC1 | HTT 242/4885TP53 4707/4885FOLH1 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.